Analyst consensus is 33% growth over next FIVE YEARS
OUT ON SEEKING ALPHA---
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) pays a 3.1% dividend yield with a dividend coverage of 3.1, and is expected to grow EPS by 33% annually for the next five years.
Questcor is a bio-pharmaceutical company and after losing 75% of its market value in a matter of days back in September 2012 the company has slowly worked its way back and is only down 8% over the past twelve months. The big fall was after fears of insurance coverage were brought to light, as well as, concerns over marketing for its key drug. The company's primary drug is H.P. Acthar Gel, which is an injectable drug that is approved for the treatment of 19 indications, namely for acute exacerbations of multiple sclerosis.
This biopharma company has one of the best "covered" dividends of the five stocks listed and a dividend yield that out paces the 30-year U.S. treasury bond. What makes Questcor even more compelling is its 0.3 PEG ratio (anything below 1.0 is a great growth at a reasonable price opportunity). Its low PEG suggests that investors are not fully appreciating the stocks ability to grow 28% annually over the next five years per analysts' estimates
I don't know what your thinking about the buyback program but you have to consider that if this company bought in over 22 million shares (thats a lot of stock for a company this size) and still have another 6+ million on their latest buyback announcement that they will buy them and anounce another as long as this stock is cheap.
How many times have they done this already?
There is no better acquisition available out there than their own.